The European Medicines Agency (EMA) yesterday approved US company Novavax's vaccine against Covid-19, also known as NVX-CoV2373 Nuvaxovid, referring it to the Commission for final formal approval.
This is the fifth vaccine, after those from Pfizer-BioNTech, Moderna, Oxford/AstraZeneca and Johnson & Johnson, to be used to fight coronavirus in the European Economic Area (27 EU plus Norway, Iceland, Liechtenstein).
Deliveries of doses of Novavax's vaccine are expected to start in the European Union in January 2022.
(CNA)
CNA
Contents of this article including associated images are owned CNA
Views & opinions expressed are those of the author and/or CNA
Source
